Investment Thesis
Zimmer Biomet demonstrates solid operational fundamentals with strong cash generation (1.5B FCF, 17.9% FCF margin) and healthy balance sheet metrics (1.98x current ratio, 0.55x debt/equity). However, the exceptional 2911% revenue growth appears anomalous and requires investigation into accounting adjustments or business combination impacts, warranting cautious optimism pending clarification of organic vs. inorganic growth drivers.
ZBH Strengths
- Robust free cash flow generation of $1.5B with 17.9% FCF margin demonstrates operational efficiency
- Conservative leverage profile with 0.55x debt/equity and 4.9x interest coverage provides financial flexibility
- Healthy liquidity position with 1.98x current ratio and 1.10x quick ratio indicates ability to meet short-term obligations
- Significant insider buying activity with 39 Form 4 filings in 90 days suggests management confidence
ZBH Risks
- Extreme 2911% YoY revenue growth is highly irregular and likely driven by accounting adjustments or acquisition rather than organic growth
- Low profitability margins (8.6% net margin, 15.6% gross margin) are concerning for a medical device company and suggest competitive pressure or integration challenges
- Diluted EPS declined 19.9% YoY despite flat net income, indicating significant share dilution from potential acquisitions
- Weak return metrics (5.6% ROE, 3.1% ROA) suggest suboptimal capital deployment despite strong cash flow generation
- Large long-term debt of $6.9B relative to stockholders equity indicates acquisition-related leverage that may constrain future flexibility
Key Metrics to Watch
- Organic vs. inorganic revenue breakdown to validate sustainability of growth rate
- Gross margin trend and product mix shift to assess competitive positioning
- Return on invested capital (ROIC) improvement as integration of acquisitions matures
- Debt reduction trajectory and free cash flow allocation between debt paydown and capital investment
- Operating margin expansion potential through synergy realization
ZBH Financial Metrics
ZBH Profitability Ratios
ZBH Balance Sheet & Liquidity
ZBH 5-Year Financial Trend
5-Year Trend Summary: ZIMMER BIOMET HOLDINGS, INC.'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $4.88 reflects profitable operations.
ZBH Growth Metrics (YoY)
ZBH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.8B | $230.9M | $1.16 |
| Q2 2025 | $1.9B | $152.8M | $0.77 |
| Q1 2025 | $1.9B | $172.4M | $0.84 |
| Q3 2024 | $1.8B | $162.7M | $0.77 |
| Q2 2024 | $1.9B | $209.6M | $1.00 |
| Q1 2024 | $1.8B | $172.4M | $0.84 |
| Q3 2023 | $1.7B | $162.7M | $0.77 |
| Q2 2023 | $1.8B | $153.7M | $0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ZBH Capital Allocation
ZBH SEC Filings
Access official SEC EDGAR filings for ZIMMER BIOMET HOLDINGS, INC. (CIK: 0001136869)